Company intelligence / Profile preview

Longevity Biotech Australia

Philadelphia, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Longevity Biotech is a preclinical-stage biopharmaceutical company focused on developing a new class of therapeutic agents called Hybridtides. These synthetic peptides are designed to be highly resistant to enzymatic degradation while maintaining the potency and specificity of natural peptides. The company's lead candidate, LBT-3627, is a neuroprotective agent targeting the VPAC2 receptor for the treatment of Parkinson's disease. By leveraging its proprietary platform, Longevity Biotech aims to address chronic diseases with high unmet medical needs, including metabolic and neurodegenerative disorders.

Therapeutic areas: EndocrinologyNeurologyGastroenterology
Modalities: PeptidesHybridtides
Industry: Biotech

Partnerships

The Michael J. Fox Foundation

Beyond the preview

Go deeper on Longevity Biotech Australia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Longevity Biotech Australia.

Explore the full profile